ClinicalTrials.gg
RecruitingNCT05872347Updated May 5, 2026

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

A Phase 2 interventional study of SPH4336 Tablets in Breast Cancer Brain Metastases, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Recruiting at 25 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 83 under way, 6 of them phase 3. Brain Neoplasms · China.

Planned enrollment
78th of 142
52 · median 60
Started
2023
with 15 others
Phase 2
60 of 179
19 open now
Primary completion
2026-12
later than 39 of 82 live
Registered
108th of 179
by date

Among the 179 studies in Brain Neoplasms with a site in China, this one is the 78th largest by planned enrollment of the 142 interventional ones that give a count, is one of 16 that started in 2023, is one of 60 in phase 2, reaches primary completion later than 39 of the 82 other live ones, and was the 108th registered.

Brain Neoplasms

2,443 studies on the registry are indexed under Brain Neoplasms; 545 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Brain Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.

03

Conditions studied

  • Breast Cancer Brain Metastases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the form (ICF).
  2. (Eastern Cooperative Oncology Group) performance status score of 0 or 1.
  3. ≥ 3 months.
  4. Patients with locally advanced or breast cancer who are unable to receive radical surgeries/other local therapies.
  5. At least one .
  6. Laboratory test results meet the relevant requirements for organ function.
  7. Subjects who agree to take effective measures.

Exclusion criteria

Exclusion Criteria:

  1. Inflammatory breast cancer.
  2. Patients unsuitable for endocrine therapy at the investigator's discretion.
  3. Have a History of other prior to the start of study treatment.
  4. Taking anti-tumor traditional Chinese patent medicines at the time of signing the ICF.
  5. Patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery.
  6. Patients who participated in a clinical trial and received other drugs before the start of study treatment.
  7. Pregnant or lactating women.
  8. History of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ (New York Heart Association) Class II; ≥ 470 ms; ≤ 50%.
  9. History of ischemic stroke or severe thromboembolic disease before the start of study treatment.
  10. surface antigen positive and HBV (Hepatitis B Virus) DNA > 2,000 IU/mL or > 10(4) copies/mL; (Hepatitis C Virus) antibody positive and HCV RNA positive; or known infection.
  11. History of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product.
  12. Presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment.
  13. Presence of uncontrolled infections before the start of study treatment.
  14. Known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders.
  15. Presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    SPH4336 Tablets

    SPH4336 Tablets; Letrozole tablets; Fulvestrant; Exemestane

    Drug: SPH4336 Tablets

Interventions

  • DrugSPH4336 Tablets

    Drug pages: SPH-4336 · CDK4/6 Inhibitor SPH4336

    SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion; Exemestane:Administered by oral.

This study also gives Fulvestrant, Exemestane. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Intracranial Objective response rate(iORR)

    Objective response rate according to response assessment in neuro-oncology-brain metastases (RANO-BM) criteria.

    Time frame: Approximately 3 years

Secondary outcomes

  1. Intracranial Duration of remission (iDOR)

    DoR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause.

    Time frame: Approximately 3 years

  2. Intracranial Disease control rate (iDCR)

    Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported.

    Time frame: Approximately 3 years

  3. Progression-free survival (PFS)

    measured by RANO-BM and RECIST 1.1

    Time frame: Approximately 3 years

  4. Overall Survival (OS)

    Determination of the overall survival times of all patients.

    Time frame: Approximately 8 years

  5. Extracranial Objective response rate(eORR)

    Objective response rate according to response assessment in neuro-oncology-brain metastases (RANO-BM) criteria.

    Time frame: Approximately 3 years

  6. Extracranial Disease control rate (eDCR)

    Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported.

    Time frame: Approximately 3 years

  7. Extracranial Duration of remission (eDOR)

    DoR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause.

    Time frame: Approximately 3 years

  8. Cmax

    PK (Pharmacokinetics) parameters

    Time frame: Approximately 3 years

  9. Tmax

    PK (Pharmacokinetics) parameters

    Time frame: Approximately 3 years

  10. Safety and tolerability

    Adverse event type, incidence, correlation with study drug

    Time frame: Approximately 3 years

07

Study locations

25 of 25 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 39 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 39 months is close to that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2023
First posted
May 24, 2023
StartActual
Sep 19, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05872347
Responsible party
Sponsor
First posted
May 24, 2023
Start date
Sep 19, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Shusen Wang
Contact
wangshs@sysucc.org.cn
0086-020-87343811

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SPH-4336 · CDK4/6 Inhibitor SPH4336

Start the discussion